Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
08:51pm, Thursday, 08'th Aug 2024
Vaxart, Inc. (NASDAQ:VXRT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ed Berg - SVP & General Counsel Steven Lo - CEO Sean Tucker - Founder & Chief Scientific Off
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
06:31pm, Thursday, 08'th Aug 2024
VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03.
Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results
04:01pm, Thursday, 08'th Aug 2024
BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart's oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats
Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8
08:00am, Friday, 02'nd Aug 2024
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
08:00am, Thursday, 27'th Jun 2024
Vaxart Inc is developing oral vaccines for COVID-19, norovirus, and influenza with promising early clinical results but financial struggles. Vaxart received $453M funding from BARDA for a 10,000-patie
Vaxart Provides Business Update
04:05pm, Monday, 17'th Jun 2024
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clini
Vaxart Announces $40 Million Underwritten Offering of Common Stock
07:07pm, Thursday, 13'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offeri
— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 23'rd May 2024
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024, the Compensation Committee of the B
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
05:49pm, Monday, 13'th May 2024
Vaxart, Inc. (NASDAQ:VXRT ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean T
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
04:01pm, Monday, 13'th May 2024
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the effect of the disease in infants
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
08:00am, Tuesday, 30'th Apr 2024
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (G
Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?
04:30pm, Tuesday, 09'th Apr 2024
The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump.
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
08:00am, Wednesday, 27'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccin
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 20'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Director
